CPGJ602 + mFOLFOX6

CPGJ602 + mFOLFOX6 is a combination therapy studied in oncology, where CPGJ602 is an investigational product (likely a novel compound, antibody, or immunomodulator) combined with the standard chemotherapy regimen mFOLFOX6. The mFOLFOX6 regimen consists of three cytotoxic agents—oxaliplatin, fluorouracil (5-FU), and leucovorin (folinic acid)—used primarily to treat gastrointestinal malignancies, especially colorectal cancer. mFOLFOX6 works by impairing DNA synthesis and function: oxaliplatin forms DNA crosslinks, fluorouracil is a pyrimidine analog inhibiting thymidylate synthase, and leucovorin enhances the binding of fluorouracil to its target enzyme. The precise mechanism of CPGJ602 is not described in the provided sources and would depend on its molecular class. Combination therapies such as these are researched to increase treatment efficacy, often in metastatic or advanced cancers[1][2][3].

Other names

CPGJ602 + mFOLFOX6